AXL-Targeting Antibody-Drug Conjugate Shows Potential for Soft-Tissue Sarcoma Treatment
A study of the AXL-directed antibody-drug conjugate ADCT-601 demonstrates significant antitumor potency and efficacy in combination with DNA damage-response inhibition ...


